- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03977987
Maternal Antiviral Treatment and Infants Immunoprophylaxis in the Prevention of Mother-to-child Transmission
June 10, 2019 updated by: Wen-hong Zhang, Huashan Hospital
Maternal Nucleos(t)Ide Analogue Use and Infants Immunoprophylaxis to Eliminate Hepatitis B Infection in the Real World Setting
The effective control of nucleos(t)ide analogues for patients infected with hepatitis B has significantly curbed the horizontal transmission of hepatitis B. However, the vertical transmission remains a serious threat to public health for directly increasing the burden of hepatitis B worldwide with the transmission rate up to 80 to 90% among high HBV DNA level if untreated.
Currently, the effective prevention of mother-to-child transmission is credited to the implement of HBV vaccination and hepatitis B virus immunoglobin.
To leave nobody behind, a growing body of evidence has been yielded to support the use of nucleos(t)ide analogues in the mothers during the late pregnancy.
However, the clinical practice can be more complex.
Therefore, investigators aim to assess the effectiveness of maternal antiviral therapy and different infants immunoprophylaxis strategy in the prevention of chronic hepatitis infection among children whose mothers were infected with chronic hepatitis B infection in the real world setting.
Study Overview
Detailed Description
From 2011 to 2017, the investigators consecutively enrolled the pregnant women with chronic hepatitis B infection who were less than 28 weeks pregnant and not treated with nucleos(t)ide analogues during pregnancy.
The investigators recommended those pregnant women with HBV DNA > 2*10^6 IU/ml to receive nucleos(t)ide analogues from 28 weeks of pregnancy to delivery.
Patients who agreed the antiviral treatment would assigned to the treatment group and those who declined it were assigned to the control group with high HBV DNA level.
Meanwhile, those pregnant women with HBV DNA < 2*10^6 IU/ml was assigned as the control group with low HBV DNA level.
All infants would be instructed to receive hepatitis B vaccine and hepatitis B virus immunoglobulin within 24 hours after birth, defined as the standard immunoprophylaxis strategy and encouraged to receive immunoprophylaxis within 2 hours after birth, defined as the aggressive immunoprophylaxis strategy.
Umbilical cord blood were collected to determine the HBV serological markers and HBV DNA level.
Children were followed every three to four years until December 2018.
Study Type
Observational
Enrollment (Actual)
233
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215400
- The First People's Hospital of Taicang
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
In the real-world setting, we recruited consecutively HBsAg positive women who were less than 28 weeks pregnant and underwent routine testing for HBV at the Department of Infectious Diseases of Taicang First People's Hospital at least twice during pregnancy.
Patients were excluded from participation if they had been treated with antiviral drugs during pregnancy.
Additional exclusion criteria were drug hypersensitivity, abnormal renal laboratory results, coinfection with human immunodeficiency virus or other human hepatitis viruses.
Description
Inclusion Criteria:
- HBsAg positive women who were less than 28 weeks pregnant and underwent routine testing for HBV at the Department of Infectious Diseases of Taicang First People's Hospital at least twice during pregnancy
Exclusion Criteria:
- women treated with antiviral drugs during pregnancy.
- drug hypersensitivity;
- abnormal renal laboratory results;
- coinfection with human immunodeficiency virus or other human hepatitis viruses.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
The treatment group
Pregnant women with high HBV DNA level > 2*10^6 IU/ml who agree to receive the antiviral treatment during the late pregnancy.
|
Pregnant women in this group agree to receive nucleos(t)ide analogue (tenofovir or telbivudine) daily from the 28 weeks of pregnancy to delivery.
|
The control group with high HBV DNA level
Pregnant women with high HBV DNA level > 2*10^6 IU/ml who decline to receive the antiviral treatment during the late pregnancy.
|
|
The control group with low HBV DNA level
Pregnant women with high HBV DNA level < 2*10^6 IU/ml
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of children who developed chronic HBV infection between the treatment group and two control groups in the real-world setting.
Time Frame: December, 2018
|
We compare the proportion of children with chronic HBV born to mothers from three groups in the real life setting
|
December, 2018
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the proportion of children who developed chronic HBV infection between the treatment group and two control groups among infants who followed the standardized immunoprophylaxis strategy
Time Frame: December, 2018
|
We compare the proportion of children with chronic HBV born to mothers from three groups who followed the standardized immunoprophylaxis strategy
|
December, 2018
|
the proportion of children who developed chronic HBV infection between the treatment group and two control groups among infants who followed the aggressive immunoprophylaxis strategy
Time Frame: December, 2018
|
We compare the proportion of children with chronic HBV born to mothers from three groups who followed the aggressive immunoprophylaxis strategy
|
December, 2018
|
The proportion of children with detectable HBV DNA and HBsAg in umbilical cord blood
Time Frame: At delivery
|
We compare the proportion of children with detectable HBV DNA and HBsAg in umbilical cord blood born to mothers from three groups
|
At delivery
|
The HBV DNA level of mothers among three groups
Time Frame: Within one week before delivery.
|
We compare the HBV DNA level of mothers among three groups within one week before delivery.
|
Within one week before delivery.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Yonglan Pu, The First People's Hospital of Taicang
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 1, 2011
Primary Completion (ACTUAL)
December 30, 2018
Study Completion (ACTUAL)
December 30, 2018
Study Registration Dates
First Submitted
June 5, 2019
First Submitted That Met QC Criteria
June 5, 2019
First Posted (ACTUAL)
June 6, 2019
Study Record Updates
Last Update Posted (ACTUAL)
June 12, 2019
Last Update Submitted That Met QC Criteria
June 10, 2019
Last Verified
June 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RWD-0
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis B
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Ain Shams UniversityCompleted
-
National Taiwan University HospitalChiayi Christian Hospital; E-DA Hospital; Taipei City Hospital; Taipei Tzu Chi... and other collaboratorsRecruitingChronic Hepatitis b | Hepatitis B ReactivationTaiwan
-
Mahidol UniversityUnknownChronic Hepatitis B, HBsAg, Hepatitis B VaccineThailand
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
IlDong Pharmaceutical Co LtdRecruitingChronic Hepatitis bKorea, Republic of
-
Antios Therapeutics, IncTerminatedChronic Hepatitis bUnited States
-
Xi'an Xintong Pharmaceutical Research Co.,Ltd.Unknown
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruitingChronic Hepatitis b | Cirrhosis Due to Hepatitis BChina
-
Zhongshan Hospital Xiamen UniversityUnknownHealthy | Chronic Hepatitis B InfectionChina
Clinical Trials on nucleos(t)ide analogue
-
Arbutus Biopharma CorporationTerminatedChronic HepatitisKorea, Republic of, Hong Kong, Thailand, Canada, Australia, Moldova, Republic of, New Zealand, Ukraine
-
Arbutus Biopharma CorporationRecruitingChronic Hepatitis bNew Zealand
-
Foundation for Liver ResearchCompleted
-
Qing XIeRecruitingChronic Hepatitis B | Intermediate to High Risk of HCCChina
-
Inovio PharmaceuticalsCompletedHepatitis BAustralia, Taiwan, United States, Singapore, New Zealand, Hong Kong, Thailand, Philippines
-
Seng Gee LimSingapore General Hospital; Tan Tock Seng Hospital; Changi General HospitalUnknown
-
Hoffmann-La RocheRecruitingChronic Hepatitis BKorea, Republic of, United States, Thailand, Hong Kong, Spain, New Zealand, Bulgaria, Taiwan, France
-
GlaxoSmithKlineActive, not recruitingHepatitis BUnited States, Netherlands, United Kingdom, Canada
-
Janssen Sciences Ireland UCCompletedHepatitis B, ChronicBelgium, Germany, United Kingdom
-
Huashan HospitalThe First Affiliated Hospital of Anhui Medical University; Beijing YouAn Hospital and other collaboratorsRecruitingChronic Hepatitis bChina